Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of inward rectifier potassium channel activity. [GOC:TermGenie, PMID:23449501]
Inward rectifier potassium (Kir) channels play a crucial role in regulating cellular excitability and maintaining resting membrane potential. Their activity is meticulously controlled by a complex interplay of factors, ensuring proper function and adaptability to cellular needs.
The regulation of Kir channel activity can be broadly categorized into two main mechanisms:
1. **Voltage-dependent gating:** Kir channels are characterized by their inward rectification property, meaning they exhibit higher conductance for inward current compared to outward current. This is attributed to the voltage-dependent blockade of the channel pore by intracellular polyamines, such as spermine and spermidine. At hyperpolarized membrane potentials, these polyamines dissociate from the channel, allowing potassium ions to flow inward. Conversely, at depolarized potentials, the polyamines bind to the channel, reducing potassium permeability and contributing to the rectification phenomenon.
2. **Modulation by intracellular signaling pathways:** Kir channels are also subject to a wide range of regulatory mechanisms mediated by intracellular signaling molecules and pathways. These include:
- **Phosphorylation:** Protein kinases, such as protein kinase A (PKA), protein kinase C (PKC), and Ca2+/calmodulin-dependent protein kinase II (CaMKII), can phosphorylate specific residues on Kir channels. Phosphorylation can either enhance or inhibit channel activity depending on the specific kinase and phosphorylation site.
- **Lipid signaling:** Phosphoinositides, such as phosphatidylinositol 4,5-bisphosphate (PIP2), can bind to Kir channels and directly modulate their activity. PIP2 binding can enhance channel opening, while its depletion can lead to channel closure.
- **G-protein coupling:** Kir channels can be coupled to G-protein-coupled receptors (GPCRs) through direct interaction or through intermediary proteins. Activation of GPCRs can lead to downstream signaling events that influence Kir channel activity.
- **Calcium signaling:** Intracellular calcium levels can directly regulate Kir channel activity through calcium-binding proteins like calmodulin.
In addition to these major mechanisms, other factors, including pH, temperature, and cellular redox state, can also influence Kir channel activity.
The intricate regulation of Kir channel activity ensures precise control of cellular excitability, contributing to a diverse range of physiological processes, including:
- **Cardiac rhythm:** Kir channels regulate the electrical activity of the heart by controlling the resting membrane potential of cardiomyocytes.
- **Neurotransmission:** Kir channels contribute to the regulation of neuronal excitability and synaptic transmission.
- **Smooth muscle contraction:** Kir channels play a role in regulating smooth muscle tone and contractility.
- **Renal function:** Kir channels are involved in the regulation of electrolyte balance and potassium homeostasis in the kidney.
Understanding the intricate mechanisms regulating Kir channel activity is crucial for comprehending the diverse physiological roles of these channels and for developing potential therapeutic strategies targeting them in disease states.
'"
Protein | Definition | Taxonomy |
---|---|---|
Integrin beta-1 | An integrin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05556] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
haloperidol | haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety. Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) | aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol | antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist |
1,3-ditolylguanidine | 1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the brain | toluenes | |
tirofiban | tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group. Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME. | L-tyrosine derivative; piperidines; sulfonamide | anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist |
arginyl-glycyl-aspartic acid | arginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition system | oligopeptide | |
arginyl-glycyl-aspartyl-serine | arginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets | ||
glycyl-arginyl-glycyl-aspartyl-serine | glycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells | ||
d-arg-gly-asp-trp | arginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide | ||
l 738167 | L 738167: structure in first source | ||
cilengitide | Cilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cells | oligopeptide | |
l 734217 | L 734217: fibrinogen receptor antagonist; structure given in first source | ||
cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
arginyl-glycyl-aspartyl-phenylalanine | |||
cyclic(arg-gly-asp-d-phe-val) | |||
mk-0429 | |||
mocetinostat | mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11). mocetinostat: undergoing phase II clinical trials for treatment of cancer | aminopyrimidine; benzamides; pyridines; secondary amino compound; secondary carboxamide; substituted aniline | antineoplastic agent; apoptosis inducer; autophagy inducer; cardioprotective agent; EC 3.5.1.98 (histone deacetylase) inhibitor; hepatotoxic agent |
tr 14035 | N-(2,6-dichlorobenzoyl)-4-(2',6'-bismethoxyphenyl)phenylalanine: TR-14035 is the (L)-isomer; an antagonist of both alpha4beta1 and beta7 integrins; structure in first source | ||
bio 1211 | BIO 1211: integrin alpha4beta1 inhibitor; structure in first source |